Target intelligence / Profile preview

Cellular communication network factor 2 (CCN2)

Target
CCN2
Molecular classification
Matricellular protein, Extracellular matrix-associated protein, Other
01

Overview

Cellular communication network factor 2 (CCN2), also known as connective tissue growth factor (CTGF), is a secreted, cysteine-rich matricellular protein comprised of four conserved modular domains (IGFBP, VWC, TSP1, CT) and is primarily involved in extracellular matrix signaling and remodeling[1][2][4]. Unlike classical growth factors, CCN2 acts as a regulatory hub by binding a variety of cell surface receptors (including integrins and LRPs) and growth factors (such as TGF-β and VEGF), thereby modulating key biological processes like cell proliferation, differentiation, angiogenesis, fibrosis, and tissue repair[1][2][4]. CCN2 is implicated in various pathological conditions, including cancer, fibrosis, and inflammatory diseases, and is being investigated as a therapeutic target and clinical biomarker, though its complex and context-dependent roles warrant careful consideration in drug development and disease monitoring[1][2][4].

Other names
Connective tissue growth factorCTGFCCN family member 2Hypertrophic chondrocyte-specific protein 24 (Hsp24)
02

Mechanism of action

Modulation of interaction with cell surface receptors and growth factors Inhibition of fibrogenic signaling Regulation of immune cell differentiation (e.g., Th17 differentiation)[3] Interference with extracellular matrix remodeling

03

Biological functions

Cell proliferationCell differentiationAngiogenesisFibrosisTissue regeneration and repairSignal transductionModulation of extracellular matrixImmune response
04

Disease associations

CancerFibrosisInflammationCardiovascular diseaseRenal diseaseOther
05

Safety considerations

Potential safety concerns involve broad effects on tissue regeneration, cell proliferation, and fibrosis, raising risks of impaired tissue healing, unwanted immunomodulation, or tumor-promoting effects depending on the context[1][2].Contradictory roles in different cancers, with both tumor-promoting and suppressing effects, complicating therapeutic approaches[2].
06

Interacting drugs

No approved drugs specifically target CCN2 directly, but experimental agents and therapeutic antibodies are in development aimed at modulating its function for fibrotic diseases and cancer[1][2][4].
07

Biomarkers

CCN2/CTGF plasma or tissue levels may serve as biomarkers for fibrotic disorders, cancer prognosis, and kidney disease, though clinical use is still under investigation[2].

Beyond the preview

Go deeper on Cellular communication network factor 2 (CCN2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular communication network factor 2 (CCN2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call